
    
      This is a phase II, multicenter, blinded within cohort, dose-escalation study to evaluate the
      safety and tolerability of two ascending doses of tralokinumab in Japanese patients aged â‰¥ 50
      years with mild to moderate Idiopathic Pulmonary Fibrosis.
    
  